Context: In type 1 diabetes (T1D), delayed gastric emptying (GE) may predispose to a mismatch between insulin delivery and glucose absorption. Previous studies evaluated, only partly, the relationship between delayed GE and postprandial, but not diurnal, glycemia. Objective: To assess the relationship between GE disturbances and glycemic control in T1D and the effects of accelerating GE on glycemic control. Design, Setting, and Participants: This was a randomized placebo-controlled trial in 30 patients with T1D on an insulin pump at an academic medical center. Intervention(s): GE was evaluated with a [13C]-Spirulina breath test at baseline (GEbaseline), during intravenous saline or erythromycin (2 or 3 mg/kg; GEiv), and after 7 days of oral erythromycin or placebo (GEoral). Weighed meals were provided throughout the study. Main Outcome Measure(s): These were GE and continuous glucose monitoring (CGM). Results: The baseline glycosylated hemoglobin was 7.6% ± 0.8% (60 ± 8.7 mmol/mol); 12 patients (40%) had delayed GE; faster GE was associated with a greater postprandial CGM-based glucose, but slower GE was not associated with postprandial hypoglycemia (<70 mg/dL). Intravenous (3 mg/kg) but not oral erythromycin accelerated GE. The relationship between GE and glycemia differed between the postprandial periods and the entire day. After adjusting for carbohydrate intake and insulin consumption, faster GE was associated with more hyperglycemia during the postprandial period but lower glucose values across the entire study. Conclusions: In T1D, pharmacologically mediated acceleration of GE increases postprandial CGM-based glucose. In contrast, delayed GE is associated with greater CGM-based glucose values over the entire day.
RCT Entities:
Context: In type 1 diabetes (T1D), delayed gastric emptying (GE) may predispose to a mismatch between insulin delivery and glucose absorption. Previous studies evaluated, only partly, the relationship between delayed GE and postprandial, but not diurnal, glycemia. Objective: To assess the relationship between GE disturbances and glycemic control in T1D and the effects of accelerating GE on glycemic control. Design, Setting, and Participants: This was a randomized placebo-controlled trial in 30 patients with T1D on an insulin pump at an academic medical center. Intervention(s): GE was evaluated with a [13C]-Spirulina breath test at baseline (GEbaseline), during intravenous saline or erythromycin (2 or 3 mg/kg; GEiv), and after 7 days of oral erythromycin or placebo (GEoral). Weighed meals were provided throughout the study. Main Outcome Measure(s): These were GE and continuous glucose monitoring (CGM). Results: The baseline glycosylated hemoglobin was 7.6% ± 0.8% (60 ± 8.7 mmol/mol); 12 patients (40%) had delayed GE; faster GE was associated with a greater postprandial CGM-based glucose, but slower GE was not associated with postprandial hypoglycemia (<70 mg/dL). Intravenous (3 mg/kg) but not oral erythromycin accelerated GE. The relationship between GE and glycemia differed between the postprandial periods and the entire day. After adjusting for carbohydrate intake and insulin consumption, faster GE was associated with more hyperglycemia during the postprandial period but lower glucose values across the entire study. Conclusions: In T1D, pharmacologically mediated acceleration of GE increases postprandial CGM-based glucose. In contrast, delayed GE is associated with greater CGM-based glucose values over the entire day.
Authors: Chinmay S Marathe; Michael Horowitz; Laurence G Trahair; Judith M Wishart; Michelle Bound; Kylie Lange; Christopher K Rayner; Karen L Jones Journal: J Clin Endocrinol Metab Date: 2015-07-14 Impact factor: 5.958
Authors: Andrea Shin; Michael Camilleri; Irene Busciglio; Duane Burton; Steven A Smith; Adrian Vella; Michael Ryks; Deborah Rhoten; Alan R Zinsmeister Journal: Clin Gastroenterol Hepatol Date: 2013-04-30 Impact factor: 11.382
Authors: Ryan Jalleh; Chinmay S Marathe; Christopher K Rayner; Karen L Jones; Michael Horowitz Journal: Curr Diab Rep Date: 2019-12-02 Impact factor: 4.810
Authors: Michael Camilleri; Richard W McCallum; Jan Tack; Sharon C Spence; Keith Gottesdiener; Fred T Fiedorek Journal: Gastroenterology Date: 2017-07-29 Impact factor: 22.682
Authors: Michael Camilleri; Victor Chedid; Alexander C Ford; Ken Haruma; Michael Horowitz; Karen L Jones; Phillip A Low; Seon-Young Park; Henry P Parkman; Vincenzo Stanghellini Journal: Nat Rev Dis Primers Date: 2018-11-01 Impact factor: 52.329
Authors: Michael Camilleri; Anthony Lembo; Richard McCallum; Stavros Tourkodimitris; Lara Kemps; Matthew B Miller; Kirk Bertelsen; Alexandru Iacob Journal: Aliment Pharmacol Ther Date: 2020-04-17 Impact factor: 8.171